The downfall of one of Japan’s most prominent CEOs is a reminder of the higher standards that come with executive-sized pay-packets, writes @GearoidReidy (via @opinion) https://t.co/KvbBA3oGWQ ...

CEO pay at top American companies rose to a median of $16.8 million in 2024. This was a 7.4% rise from just the year before, and it's part of a long-term trend that's been going on for decades. Meanwhile, the average worker's pay rose by less than 4% in the same period, which is not enough to keep up with inflation. Numbers like these matter in debates about inequality, corporate governance, and worker morale. This article breaks down how executives are paid, how their pay has changed over time, and how ...

The thing Tesla is selling hardest these days is the idea that Elon Musk needs to be paid more, the WSJ’s Tim Higgins writes https://t.co/dM0tk7h2G7 ...

Compensation for UK-based executives at the country’s largest firms is rising, narrowing a pay gap with US peers that has contributed to an exodus of companies from London https://t.co/xHcs3ZkAog ...

Annual pay for bosses of FTSE 100 companies hit a record high for the third consecutive year https://t.co/Ef5FMyvX5p ...

Hired-Hand Billionaires 2025: These 48 Executives Got Rich Working For Others https://t.co/z93N1OLLMs https://t.co/z93N1OLLMs ...

Executive Compensation - The report identifies 48 executives who became billionaires through working as employees [1] - The report focuses on executives who accumulated wealth by working for others, rather than founding their own companies [1]

Executive Compensation - The report highlights a new milestone in executive compensation: the billion-dollar year for CEOs of major U S companies [1]

Core Points - Wheaton Precious Metals Corp. held its 2025 Annual and Special Meeting of Shareholders where nominees for the Board of Directors were elected [1][3] - The company announced the passing of long-serving director Peter Gillin, who will be remembered for his contributions [2] - Shareholders approved a non-binding advisory resolution on executive compensation with 94.94% votes in favor [3] Board of Directors Election Results - George L. Brack received 320,198,848 votes (97.83% for) with 7,090,095 votes withheld (2.17% withheld) [3] - Jaimie Donovan received 323,374,043 votes (98.80% for) with 3,914,900 votes withheld (1.20% withheld) [3] - Chantal Gosselin received 312,988,404 votes (95.63% for) with 14,300,539 votes withheld (4.37% withheld) [3] - Jeane Hull received 322,832,980 votes (98.64% for) with 4,455,963 votes withheld (1.36% withheld) [3] - Glenn Ives received 326,462,793 votes (99.75% for) with 826,150 votes withheld (0.25% withheld) [3] - Charles A. Jeannes received 321,612,216 votes (98.27% for) with 5,676,727 votes withheld (1.73% withheld) [3] - Marilyn Schonberner received 324,225,349 votes (99.06% for) with 3,063,594 votes withheld (0.94% withheld) [3] - Randy V.J. Smallwood received 326,818,313 votes (99.86% for) with 470,630 votes withheld (0.14% withheld) [3] - Srinivasan Venkatakrishnan received 324,453,056 votes (99.13% for) with 2,835,887 votes withheld (0.87% withheld) [3]

Financial Data and Key Metrics Changes - Total net revenues for 2024 were $56.3 billion, exceeding initial expectations by over $2 billion [4] - Adjusted earnings per share were $10.12, which was $0.49 above the initial guidance midpoint, excluding the impact of IPR&D expense [4] - The company demonstrated a rapid return to sales growth following the loss of exclusivity for HUMIRA, with expectations to exceed previous peak revenue in 2025 [4][5] Business Line Data and Key Metrics Changes - AbbVie's growth platform delivered full-year sales growth of over 18%, allowing the company to absorb the largest loss of exclusivity in the industry and continue investing for long-term growth [5] - Adjusted R&D investment increased by $3 billion, with approximately 20 early-stage deals signed and acquisitions of ImmunoGen and Cerevil completed [5] Market Data and Key Metrics Changes - The company is well-positioned to deliver high single-digit compound revenue growth through the end of the decade [5] Company Strategy and Development Direction - AbbVie is focused on assets that can add depth to its pipeline and drive growth over the next decade, with significant investments in R&D and business development [23] - The company has expanded its immunology portfolio and entered new therapeutic areas such as obesity, which represents a potential new source of long-term growth [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in AbbVie's ability to rapidly return to growth despite challenges related to HUMIRA's loss of exclusivity [21] - The company plans to invest over $10 billion in U.S. manufacturing capacity to support volume growth and expansion into new areas [29] Other Important Information - The board of directors opposed a shareholder proposal for a simple majority vote, stating that even if it passed, it would not eliminate the supermajority voting requirement [18] Q&A Session Summary Question: Will AbbVie continue to raise the dividend in coming years? - AbbVie generates substantial free cash flow, allowing it to support a strong and growing dividend, which was increased by 5.8% in Q1 2025 [21][22] Question: Is AbbVie considering additional M&A deals to support long-term growth? - AbbVie is focused on acquiring assets that can enhance its pipeline, including recent acquisitions in immunology and oncology [23][24] Question: Why did AbbVie decide to combine the CEO and Chair roles again? - The board believes that a combined leadership structure has proven effective and ensures appropriate oversight and independence [25] Question: How will sectoral tariffs on pharmaceuticals impact AbbVie? - It is premature to speculate on the impact of sectoral tariffs, but AbbVie plans to mitigate any potential effects through inventory management and cost efficiency initiatives [27][28] Question: How has the pipeline progressed in the past year? - AbbVie achieved several regulatory approvals and is advancing multiple pipeline programs that could be significant sources of long-term growth [32][33]